Earnings Feed
Start Free
Home/Filings/4/0001104659-15-053968
4//SEC Filing

Neos Therapeutics, Inc. 4

Accession 0001104659-15-053968

CIK 0001467652operating
View on SEC.govCompany Profile

Filed

Jul 27, 8:00 PM ET

Accepted

Jul 28, 8:28 PM ET

Size

25.1 KB

Accession

0001104659-15-053968

Insider Transaction Report

Form 4
Period: 2015-07-27
Neos Therapeutics, Inc.NEOS
HELLER ALAN L
Director
Transactions
  • Conversion

    Common Stock

    2015-07-28+100,000→ 277,932 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2015-07-27−28,897→ 0 total
    Exercise: $2.31Exp: 2022-11-14→ Common Stock (28,897 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2015-07-27−1,643→ 0 total
    Exercise: $0.32Exp: 2021-08-30→ Common Stock (1,643 underlying)
  • Conversion

    Series B-1 Preferred Stock

    2015-07-28−240,000→ 0 total
    → Common Stock (100,000 underlying)
  • Exercise of In-Money

    Common Stock

    2015-07-27$0.02/sh+16,408$394→ 126,559 total
  • Exercise/Conversion

    Common Stock

    2015-07-27$0.32/sh+1,643$526→ 157,099 total
  • Conversion

    Common Stock

    2015-07-28+20,833→ 177,932 total
  • Conversion

    Series B Preferred Stock

    2015-07-28−50,000→ 0 total
    → Common Stock (20,833 underlying)
  • Conversion

    Series C Preferred Stock

    2015-07-28−220,700→ 0 total
    → Common Stock (91,956 underlying)
  • Exercise/Conversion

    Common Stock

    2015-07-27$2.31/sh+28,897$66,752→ 155,456 total
  • Conversion

    Common Stock

    2015-07-28+91,956→ 369,888 total
  • Exercise of In-Money

    Common Stock Warrant (Right to Buy)

    2015-07-27−16,408→ 0 total
    Exercise: $0.02Exp: 2016-10-19→ Common Stock (16,408 underlying)
Footnotes (3)
  • [F1]Each share of the Issuer's Series B preferred stock, Series B-1 preferred stock and Series C preferred stock was automatically converted on a 2.4-for-1 basis into common stock immediately prior to the closing of the Issuer's initial public offering. The shares of Series B preferred stock, Series B-1 preferred stock and Series C preferred stock had no expiration date.
  • [F2]The warrant was exercisable at any time at the holder's election.
  • [F3]This stock option was fully vested and exercisable.

Documents

1 file

Issuer

Neos Therapeutics, Inc.

CIK 0001467652

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001467652

Filing Metadata

Form type
4
Filed
Jul 27, 8:00 PM ET
Accepted
Jul 28, 8:28 PM ET
Size
25.1 KB
View on SEC.gov